Agree that the B-OM phase 3 will be inexpensive compared to most clinical trials. Per the 10-Q dated 2/8/19 " the Company’s planned operations, including total budgeted expenditures of approximately $13.5 million for the next twelve months". I don't think IPIX would declare a budget that does not include running the B-OM ph3 which is the top priority for the company. Note that the previous 2 year expense rate was around $12M/yr with multiple trials going on in that time frame. Also note that Dr. Bertolino's strategy was to not proceed with ABSSSI phase 3 due to the $30M estimated cost and redirected resources to get Brilacidin to market more quickly and inexpensively with B-OM and B-IBD as well as opening much larger revenue potential.